BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)

This is an educational mention, not an actionable investment signal for either stock.

What the company is saying

The announcement communicates that Broadridge Financial Resources Inc. (NYSE: BR) has been selected as the 'Stock to Study' and ResMed Inc. (NYSE: RMD) as the 'Undervalued Stock' in the October 2026 issue of BetterInvesting Magazine. The core narrative is that these selections are intended to help investors learn how to analyze stocks, not to serve as buy recommendations. The language is explicit: these choices are for informational and educational purposes only and are not to be considered as endorsements or recommendations for purchase by NAIC/BetterInvesting. The announcement emphasizes the availability of free and trial educational resources, such as online lessons and stock analysis tools, to support investor self-education. It also highlights the credentials of the Editorial Advisory and Securities Review Committee—Dan Rutter, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; and Anne Nichols, CFA—who are responsible for the selections, signaling a process led by credentialed professionals. However, the announcement buries or omits any discussion of the actual financial or operational merits of Broadridge Financial Resources Inc. or ResMed Inc.; no numbers, growth rates, or business context are provided. The tone is neutral, factual, and careful to avoid any implication of investment advice, with repeated disclaimers about the non-recommendation status of the selections. The communication style is didactic and compliance-oriented, focusing on investor education and risk avoidance. The involvement of multiple CFAs on the committee lends credibility to the selection process, but their institutional roles are not specified beyond committee membership, so their participation should be interpreted as procedural rather than as a signal of personal or institutional conviction. This narrative fits into BetterInvesting's broader strategy of promoting financial literacy and responsible investing, positioning itself as a resource for self-directed investors rather than as a source of actionable stock picks.

What the data suggests

The disclosed numbers in the announcement are limited to organizational facts about BetterInvesting, such as its 501(c)(3) nonprofit status, its founding year (1951), and the claim that it has helped more than 5 million people. There are no financial results, operational metrics, or valuation data provided for either Broadridge Financial Resources Inc. or ResMed Inc. No revenue, earnings, cash flow, or growth rates are disclosed, and there is no information about recent financial performance or business trajectory for either company. The gap between what is claimed and what is evidenced is total: while the announcement frames the stocks as worthy of study or potentially undervalued, it provides no supporting data or analysis to justify these designations. There is no mention of whether either company has met or missed prior targets or guidance, nor is there any context for why these stocks were chosen. The quality and completeness of the financial disclosures are extremely poor from an investment analysis perspective; key metrics are entirely absent, and there is no way to compare these companies to peers or to their own past performance. An independent analyst, relying solely on the numbers in this announcement, would conclude that there is no basis for any investment decision regarding NYSE:BR or NYSE:RMD. The only actionable data relates to BetterInvesting's educational mission, not to the investment merits of the named companies.

Analysis

The announcement is strictly informational, disclosing that Broadridge Financial Resources Inc. and ResMed Inc. have been selected as 'Stock to Study' and 'Undervalued Stock' respectively by BetterInvesting Magazine for October 2026. There are no forward-looking statements, projections, or claims of future performance for either company. No financial, operational, or profitability metrics are disclosed, and there is no mention of capital outlays or expected benefits. The language is factual and includes explicit disclaimers that the selections are not recommendations. There is no evidence of narrative inflation or overstatement, as the announcement does not attempt to frame the selections as investment opportunities or imply any immediate or future benefit to investors.

Risk flags

• ●The primary risk is that investors may misinterpret the 'Stock to Study' and 'Undervalued Stock' labels as buy recommendations, despite explicit disclaimers to the contrary. This matters because acting on these designations without supporting data could lead to uninformed investment decisions.
• ●There is a complete lack of financial, operational, or valuation data for either NYSE:BR or NYSE:RMD in the announcement. This absence of disclosure means investors have no basis for assessing risk, reward, or suitability, increasing the chance of misallocation of capital.
• ●The announcement provides no context or rationale for why these particular stocks were selected, leaving investors in the dark about the underlying criteria or analysis. This opacity is a material risk, as it prevents independent verification or critical assessment.
• ●The involvement of multiple CFAs on the committee may lend an aura of credibility, but their roles are limited to selection for educational purposes, not investment endorsement. Investors may overestimate the significance of their participation, which is procedural rather than conviction-based.
• ●No forward-looking statements or projections are made, but the absence of any financial or operational context means that investors cannot assess future risks or opportunities for either company. This lack of transparency is itself a risk.
• ●The announcement is issued by a nonprofit educational organization, not by the companies themselves, so there is no assurance that the information is current, comprehensive, or reflective of the companies' actual business outlooks.
• ●Because the announcement is strictly informational and educational, there is a risk that investors seeking actionable signals may waste time or resources pursuing further research based on these selections, only to find no substantive investment case.
• ●The explicit disclaimers that these are not recommendations may not be heeded by all readers, especially less experienced investors, leading to potential misinterpretation and unintended risk-taking.

Bottom line

For investors, this announcement is not a signal to buy, sell, or hold either Broadridge Financial Resources Inc. (NYSE: BR) or ResMed Inc. (NYSE: RMD). The selections as 'Stock to Study' and 'Undervalued Stock' are purely educational designations made by a nonprofit organization for the October 2026 issue of BetterInvesting Magazine, with no supporting financial or operational data provided. The narrative is credible in its transparency about the non-recommendation status of these choices, but it offers no substantive information about the companies themselves. The presence of multiple CFAs on the selection committee indicates a process led by credentialed professionals, but their involvement should not be interpreted as a signal of institutional or personal investment conviction. To change this assessment, the announcement would need to disclose actual financial results, valuation metrics, or a clear rationale for the selections. Investors should watch for future disclosures from the companies themselves—such as earnings releases, guidance updates, or operational milestones—rather than relying on this educational mention. This announcement should be weighted as a non-actionable informational item: it may prompt further research, but it does not provide any basis for an investment decision. The single most important takeaway is that these designations are not investment recommendations and should not be treated as such; investors must seek out actual financial data and analysis before considering any action.

Announcement summary

(NYSE: BR) Broadridge Financial Resources Inc. was announced as the 'Stock to Study' by the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine in the October 2026 issue. ResMed Inc. (NYSE: RMD) was named as the 'Undervalued Stock' in the same issue for investors' informational and educational use. BetterInvesting offers a number of free resources, including online lessons and stock selection and analysis tools, to help investors study the investment potential of Broadridge Financial and ResMed by viewing their fundamental data and applying judgments. Committee members include Dan Rutter, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; and Anne Nichols, CFA. BetterInvesting is a national 501(c)(3) nonprofit, investment education organization that has helped more than 5 million people since 1951. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools. The Stock to Study and Undervalued Stock choices are for informational and educational uses only and are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting.

Disagree with this article?